Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

Apr 17, 2019

SELL
$98.85 - $134.59 $320,076 - $435,802
-3,238 Closed
0 $0
Q4 2018

Jan 31, 2019

SELL
$63.81 - $109.82 $10,592 - $18,230
-166 Reduced 4.88%
3,238 $311,000
Q3 2018

Nov 13, 2018

BUY
$75.5 - $96.63 $257,002 - $328,928
3,404 New
3,404 $258,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Wedbush Securities Inc Portfolio

Follow Wedbush Securities Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wedbush Securities Inc with notifications on news.